18
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T16899 |
SMCC-DM1
DM1-SMCC |
Others | Others |
SMCC-DM1 (DM1-SMCC) 是一种药物-接头偶联物,由有效的微管破坏剂 DM1 和接头 SMCC 组成,用于制备抗体药物偶联物。 | |||
T21408 |
DM1-SMe
DM1-SSMe |
Microtubule Associated | Cytoskeletal Signaling |
DM1-SMe (DM1-SSMe) 是美登木素微管的有效抑制剂。 DM1-SMe 的效力是母体药物美登素的 3 至 10 倍,在一组人类肿瘤细胞系中,DM1-SMe 的 IC50 为 0.003 至 0.01 nM。 | |||
T11917 |
Lys-SMCC-DM1
Lys-Nε-MCC-DM1 |
Microtubule Associated | Cytoskeletal Signaling |
DM1 是一种微管蛋白抑制剂。 Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) 是 DM1 的活性代谢物。 | |||
T1992 |
Mertansine
DM1,Maytansinoid DM1 |
Microtubule Associated | Cytoskeletal Signaling |
Mertansine (DM1) 是一种微管蛋白抑制剂,也是一种抗体可缀合的美登木素生物碱。它通过连接体连接到单克隆抗体上,形成抗体偶联药物。 | |||
T38493 |
MCC-DM1
MCC-DM1 |
||
MCC-DM1 is a drug-Linker Conjugates for ADC such ad Anti-CD22-MCC-DM1. | |||
T38788 |
MC-DM1
MC-DM1 |
||
MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC). | |||
T24007 |
DM1-MCC
MCC-DM1 |
Others | Others |
DM1-MCC (MCC-DM1) 是一种具有 MCC 接头的抗癌药物 DM1。 | |||
T18718 |
SPP-DM1
|
Others | Others |
SPP-DM1, a drug-linker conjugate for antibody-drug conjugates (ADC), demonstrates potent antitumor activity. It comprises DM1 (a potent microtubule-disrupting agent) connected through the ADC linker SPP[1]. | |||
T12805 |
S-methyl DM1
|
Microtubule Associated | Cytoskeletal Signaling |
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin(Kd of 0.93 μM) and inhibts microtubule polymerization. | |||
T17832 |
DM1-PEG4-DBCO
|
Others | Others |
DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid. | |||
T18305 |
Mal-VC-PAB-DM1
|
Others | Others |
Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1]. | |||
T18678 |
SC-VC-PAB-DM1
|
Others | Others |
SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity. | |||
T77848 |
vc-PABC-DM1
|
||
vc-PABC-DM1用于合成基于二硫键的ADC分子,且可探索其血清稳定性。 | |||
T82173 |
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM
|
||
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM 是一种用于抗体偶联药物(ADC)的药物连接体。其中DM代表了maytansinoid组分。 | |||
T62403 | DM-01 | ||
DM-01 是一种强效的、选择性的 EZH2 抑制剂。DM-01 能够用于研究弥漫性大 B 细胞淋巴瘤 (DLBCL),滤泡性淋巴瘤 (FL) 和 SNF5/INI-1/SMARCB1 基因相关实体瘤。 | |||
T73948 | Duocarmycin DM | ||
Duocarmycin DM,一种DNA小沟烷基化剂(DNA minor-groove alkylator),作为抗体活性分子结合物(ADCs)的毒素,因其独特结构显示出抗癌活性。 | |||
T75100 | DM-CO-(CH2)5-SMe | ||
DM-CO-(CH2)5-SMe,一种源自抗体活性分子偶联物(ADC)代谢产物的抗癌剂,对H1703、H1975、COLO704及Colo720E细胞展现出细胞毒性。 | |||
T80712 |
α-Glucosidase-IN-38
|
Glucosidase | Metabolism |
α-Glucosidase-IN-38 (Compound 11j) is an effective α-glucosidase inhibitor with an IC50 of 12.44±0.38 μM, playing a significant role in diabetes mellitus (DM). |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T83089 |
Anticancer agent 149
|
||
Anticanceragent 149 (compound 3) 是一种从薯蓣 (DM) 根茎中分离出的抗癌剂,其对MCF-7 细胞呈现选择性细胞毒活性,特有IC50值为31.41 μM。 | |||
TN4108 | Ganoderic acid Z | Antifection | Microbiology/Virology |
The binding affinities of ganoderic acid DM and ganoderic acid Z (ÎGbind, -16.83 and-10.99 kcal mol-1) are comparable to that of current commercial drug oseltamivir (-23.62 kcal mol-1);Ganoderic acid DM is a potential source of anti-influenza ingredient, with novel binding pattern and advantage over oseltamivir, it has steric hindrance on the 150 cavity of N1 protein, and exerts activities across the H274Y and N294S mutations, is the attractive candidates of novel neuraminidase (NA) inhibitors.... |